Lineage Cell Therapeutics Inc (LCTX)

$1.53 +0.02 (1.32%)
Market Cap 381.11M
Revenue (ttm) 14.56M
Net Income (ttm) -63.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -436.33%
Debt to Equity Ratio 0.00
Volume 1,362,800
Avg Vol 1,166,148
Day's Range N/A - N/A
Shares Out 249.09M
Stochastic %K 32%
Beta 1.60
Analysts Strong Sell
Price Target $5.14

Company Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 442 287 8990
Address:
2173 Salk Avenue, Suite 200, Carlsbad, United States
keoni137
keoni137 May. 4 at 4:21 PM
$LCTX Is this some sort of sell the news situation going on here?
0 · Reply
RBT1369
RBT1369 May. 4 at 2:25 PM
$LCTX it appears that this OpRegen shit works
2 · Reply
DiligentInvesting
DiligentInvesting May. 4 at 1:46 PM
$LCTX
0 · Reply
Special_Elvis
Special_Elvis May. 4 at 1:33 PM
$LCTX The new presentation seems to have more detail than the one from 2025 https://investor.lineagecell.com/static-files/ec328fec-3719-404b-ba49-c1b9a4aec9e4
2 · Reply
Shaftertoz
Shaftertoz May. 4 at 1:33 PM
@Ablidy Hello, Thank you for your work. What do you think about the $LCTX announcements, particularly the 3-year results? Thank you.
1 · Reply
ausmak
ausmak May. 4 at 1:31 PM
$LCTX should I get out?
1 · Reply
Trak2
Trak2 May. 4 at 1:19 PM
$LCTX is it a fair assumption, that the delivery device is 100 times better than the original one that LCTX used from three years ago? so should we expect better results now? three years later and it’s still working.thank you
1 · Reply
alphadog10
alphadog10 May. 4 at 1:14 PM
$LCTX Claude called him tone deaf lol
0 · Reply
alphadog10
alphadog10 May. 4 at 1:12 PM
$LCTX John, Z06, Permabulls what do you think
0 · Reply
alphadog10
alphadog10 May. 4 at 12:38 PM
$LCTX Fire this guy 🙏
0 · Reply
Latest News on LCTX
Lineage Announces Formation of Scientific Advisory Board

Apr 13, 2026, 8:00 AM EDT - 21 days ago

Lineage Announces Formation of Scientific Advisory Board

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Mar 24, 2026, 8:00 AM EDT - 5 weeks ago

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

Lineage Cell Therapeutics Earnings Call Transcript: Q4 2025

Mar 5, 2026, 4:30 PM EST - 2 months ago

Lineage Cell Therapeutics Earnings Call Transcript: Q4 2025

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 4:01 PM EST - 2 months ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Feb 26, 2026, 8:00 AM EST - 2 months ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Jan 6, 2026, 8:00 AM EST - 4 months ago

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Lineage Cell Therapeutics Issues Letter to Stockholders

Jan 5, 2026, 8:00 AM EST - 4 months ago

Lineage Cell Therapeutics Issues Letter to Stockholders

Lineage Cell Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 6 months ago

Lineage Cell Therapeutics Earnings Call Transcript: Q3 2025

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:01 PM EST - 6 months ago

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Lineage Cell Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:30 AM EDT - 8 months ago

Lineage Cell Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 8 months ago

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Aug 26, 2025, 8:00 AM EDT - 8 months ago

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2025

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Aug 5, 2025, 8:00 AM EDT - 9 months ago

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Aug 4, 2025, 8:00 AM EDT - 9 months ago

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Two Biotech Stocks Poised For Big Moves On Monday

Jun 23, 2025, 7:39 AM EDT - 11 months ago

Two Biotech Stocks Poised For Big Moves On Monday

SANA

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Jun 23, 2025, 7:00 AM EDT - 11 months ago

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

Jun 5, 2025, 8:00 AM EDT - 11 months ago

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

Lineage Cell Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 2:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 14, 2025, 8:00 AM EDT - 1 year ago

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2025

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Lineage Cell Therapeutics Earnings Call Transcript: Q4 2024

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q4 2024

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Mar 5, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Lineage Cell Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 12:40 PM EST - 1 year ago

Lineage Cell Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Jan 27, 2025, 4:05 PM EST - 1 year ago

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Nov 21, 2024, 5:00 PM EST - 1 year ago

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Nov 20, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Lineage Cell Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q3 2024

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Sep 25, 2024, 8:00 AM EDT - 1 year ago

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Lineage Cell Therapeutics Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2024

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

Lineage to Present at 2024 BIO International Convention

May 30, 2024, 8:00 AM EDT - 2 years ago

Lineage to Present at 2024 BIO International Convention

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

May 21, 2024, 8:00 AM EDT - 2 years ago

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2024

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:01 PM EDT - 2 years ago

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

May 6, 2024, 8:00 AM EDT - 2 years ago

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Lineage Announces Changes to Board of Directors

Apr 29, 2024, 4:30 PM EDT - 2 years ago

Lineage Announces Changes to Board of Directors

Lineage Announces Appointment of New Board Member

Apr 23, 2024, 8:05 AM EDT - 2 years ago

Lineage Announces Appointment of New Board Member

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Mar 13, 2024, 8:00 AM EDT - 2 years ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

keoni137
keoni137 May. 4 at 4:21 PM
$LCTX Is this some sort of sell the news situation going on here?
0 · Reply
RBT1369
RBT1369 May. 4 at 2:25 PM
$LCTX it appears that this OpRegen shit works
2 · Reply
DiligentInvesting
DiligentInvesting May. 4 at 1:46 PM
$LCTX
0 · Reply
Special_Elvis
Special_Elvis May. 4 at 1:33 PM
$LCTX The new presentation seems to have more detail than the one from 2025 https://investor.lineagecell.com/static-files/ec328fec-3719-404b-ba49-c1b9a4aec9e4
2 · Reply
Shaftertoz
Shaftertoz May. 4 at 1:33 PM
@Ablidy Hello, Thank you for your work. What do you think about the $LCTX announcements, particularly the 3-year results? Thank you.
1 · Reply
ausmak
ausmak May. 4 at 1:31 PM
$LCTX should I get out?
1 · Reply
Trak2
Trak2 May. 4 at 1:19 PM
$LCTX is it a fair assumption, that the delivery device is 100 times better than the original one that LCTX used from three years ago? so should we expect better results now? three years later and it’s still working.thank you
1 · Reply
alphadog10
alphadog10 May. 4 at 1:14 PM
$LCTX Claude called him tone deaf lol
0 · Reply
alphadog10
alphadog10 May. 4 at 1:12 PM
$LCTX John, Z06, Permabulls what do you think
0 · Reply
alphadog10
alphadog10 May. 4 at 12:38 PM
$LCTX Fire this guy 🙏
0 · Reply
DiligentInvesting
DiligentInvesting May. 4 at 12:24 PM
$LCTX Gemini
2 · Reply
alphadog10
alphadog10 May. 4 at 12:24 PM
$LCTX Surpised BW didnt invest in $AXSM instead of this dumpster back in the day. Wow !
0 · Reply
alphadog10
alphadog10 May. 4 at 12:23 PM
$LCTX How many times will they share old regurgitated data? 😂
0 · Reply
DiligentInvesting
DiligentInvesting May. 4 at 12:14 PM
$LCTX Ok so how are these results different from last year's? https://finance.yahoo.com/news/opregen-rg6501-36-month-visual-110000682.html
1 · Reply
eughuge
eughuge May. 4 at 12:05 PM
$LCTX OpRegen 3 year results out. Your views would be interesting to hear.
1 · Reply
Special_Elvis
Special_Elvis May. 4 at 12:03 PM
$LCTX https://investor.lineagecell.com/news-releases/news-release-details/opregenr-3-year-results-patients-ga-presented-foundation
0 · Reply
dannyschell
dannyschell May. 4 at 1:30 AM
$LCTX can anyone offer a reason why this won’t continue a downward trajectory until 29?
1 · Reply
alphadog10
alphadog10 May. 3 at 8:36 PM
$LCTX I'll have to admit, 4 years ago i had no idea they'd print that many shares during the wait i completely underestimated Culley. I only thought he was a subpar CEO back then time has shown everyone hes absolutely terrible.
0 · Reply
alphadog10
alphadog10 May. 3 at 8:32 PM
$LCTX Reality is always ugly. Its no wonder people prefer dreaming over reality
0 · Reply
alphadog10
alphadog10 May. 3 at 8:30 PM
$LCTX 📅 long time ago
0 · Reply
DiligentInvesting
DiligentInvesting May. 3 at 5:14 PM
$LCTX Fo sho a lot of fud being spread tossed around lately.
0 · Reply
Turnerjack27
Turnerjack27 May. 3 at 5:08 PM
$LCTX This post was from 2022. Pretty prescient, i thought lecturer was full of shit at the time. My take away from this is that we were supposed to "trust the science" behind a covid vax that got a free run through the fda in 9 months. We've had to watch complement inhibition get accepted into treatment of GA. Shareholders of these companies had "perfect" timing after years of spinning their tires in the mud. Meanwhile we are diluting shareholders as ive seen outstanding shares in Lineage increase 50% in the 6 years ive held this stock. Follow the money.
0 · Reply